Key Drivers
- Strong liquidity
- High cash‑burn
- Rich valuation
AIAI Summary
Intellia has shifted from a long‑dated, single‑CRISPR bet to a near‑term, event‑driven investment where a successful mid‑2026 lonvo‑z HAE readout (and H2‑2026 BLA timing) can materially de‑risk the story and justify current valuation; monitor that readout and the company's ability to demonstrate clear mitigation of nex‑z liver safety signals. If safety issues persist or burn remains high forcing dilutive financing, downside is acute—so track readout data, quarterly cash burn/runway, and any near‑term financing activity as the gating metrics.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High cash‑burn
- •Rich valuation
NTLA combines a strong balance sheet and low leverage with heavy cash burn, sizable R&D-driven losses, and a premium valuation despite improving quarterly operating trends.
Price Behavior
Key Price Behavior Insights:
- •Intermediate gain
- •Short-term weakness
- •High volatility
Despite a roughly 9.7% gain over the last month, the stock has pulled back ~17% from a recent $15.44 high and now trades below its last month average—indicating intermediate strength but short-term momentum softness and elevated volatility;
~17% pullback from $15.44 peak with ~one-third intraperiod range indicating elevated volatility
Sentiment & News
Key News Insights:
- •FDA hold lifted
- •Q4 beat
- •Investor buying
Intellia reported narrower losses and revenue beats, won FDA clearance to resume the MAGNITUDE Phase 3 nex-z trial, presented positive lonvo-z data, and drew investor interest amid hiring and equity grants.
The FDA lift and clinical data materially de-risk near-term program milestones and should support upside in sentiment, though mixed analyst ratings keep valuation gains moderate
Similar Companies in Healthcare
Other companies in the same sector with AI ratings